You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

RELENZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Relenza, and when can generic versions of Relenza launch?

Relenza is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in RELENZA is zanamivir. One supplier is listed for this compound. Additional details are available on the zanamivir profile page.

Drug patent expirations by year for RELENZA
Drug Prices for RELENZA

See drug prices for RELENZA

Recent Clinical Trials for RELENZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of OxfordPhase 2
Food and Health Bureau, Hong KongPhase 3
Chinese University of Hong KongPhase 3

See all RELENZA clinical trials

Pharmacology for RELENZA
Drug ClassNeuraminidase Inhibitor
Mechanism of ActionNeuraminidase Inhibitors

US Patents and Regulatory Information for RELENZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RELENZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for RELENZA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
GlaxoSmithKline Trading Services Limited Dectova Zanamivir EMEA/H/C/004102
Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance.
Authorised no no no 2019-04-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for RELENZA

See the table below for patents covering RELENZA around the world.

Country Patent Number Title Estimated Expiration
African Intellectual Property Organization (OAPI) 9679 ⤷  Try a Trial
New Zealand 217006 INHALER FOR FINELY DIVIDED MEDICAMENT INCLUDES PLUNGER TO OPEN MEDICAMENT CONTAINER ⤷  Try a Trial
France 2550452 DISPOSITIF POUR ADMINISTRER DES MEDICAMENTS A DES PATIENTS ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for RELENZA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0208846 99C0032 Belgium ⤷  Try a Trial PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: NL 24 551 19990726; FIRST REGISTRATION: SE - 14 997 19990209
0526543 990030 Netherlands ⤷  Try a Trial PRODUCT NAME: ZANAMIVIRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBARE ESTER; NATL. REGISTRATION NO/DATE: RVG 24094 19990707; FIRST REGISTRATION: SE 14997 19990209
0526543 SPC/GB99/030 United Kingdom ⤷  Try a Trial PRODUCT NAME: ZANAMIVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE; REGISTERED: SE 14997 19990209; UK PL10949/0327 19990625
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.